Loading
Adaptive Biotechnologies Corp Stock: price and insider trades · United States
Adaptive Biotechnologies Corp: what insiders have been doing
Adaptive Biotechnologies Corp, classified in the Healthcare & Pharma sector, is a listed company based in Seattle, United States, founded in 2009. Its insiders report their share dealings to SEC (Form 4). The last twelve months, up to 18 October 2026, brought 214 filings signed by 21 insiders.
Only sales appear on the open market, 93 sales in all totalling €68.5M, filed by 11 insiders. The totals exclude 7 filings filed without an amount. The largest single trade was a sale of €6.9M by Robins Chad M, published on 19 August 2026, equal to 0.18% of the market capitalisation.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Compared with its exchange (5,816 companies, median 19 filings), a count of 214 filings is above the norm. Looking back to 2021, when coverage begins, insiders filed no purchases and 128 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 277.0 m USD and net income of -59.5 m USD.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
360
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€76M
128 ops. · all time
Who traded when
BuySaleJulie Rubinstein32 sales
Chad M. Robins14 sales
Harlan S. Robins13 sales
Francis Lo12 sales
Susan Bobulsky10 sales
Kyle Piskel5 sales
+5 other insiders
Analyst consensus: bullish or bearish?
Analysts rate Adaptive Biotechnologies Corp Strong Buy (bullish), based on 8 analysts. Average price target: US$29.81.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 18,928 of 24,148 companies
32.1
score / 100
Value29
Quality35
FCF yld-1.3%
Earn yld-1.6%
EV/EBITDA·
ROE-39%
Gross mgn74%
Net mgn-21%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$25.62
Analyst consensus
8 analystsStrong buy
US$21.00Target US$29.81(+16%)US$35.00
Income statement
RevenueUS$277M
Gross profitUS$205.6M74% margin
EBITDA-US$29.8M-11% margin
Net income-US$59.5M-20.7% margin
Valuation
PER (forward)-142.1x
P/Book28.5x
Beta2.10
Balance sheet & cash
Market capUS$4.1B
Total debtUS$79.1M
Free Cash Flow-US$48.9M
Debt / Equity272%
Profitability & ownership
ROE-38.8%
ROA-4.1%
% insiders1.3%
% institutions99.3%
Last declaration on 16 October 2026
Declarations360 total
11,881 shares@ US$12.14Common StockSEC:0001780664-26-000041:0
6,781 shares@ US$25.57Common StockSEC:0001780664-26-000041:1
5,100 shares@ US$25.82Common StockSEC:0001780664-26-000041:2
11,881 shares@ US$12.14Common StockSEC:0001780664-26-000041:3
11,881 shares@ US$25.61Common StockSEC:0001780664-26-000041:4
11,881 shares@ US$12.14Common StockSEC:0001780664-26-000041:5
11,581 shares@ US$24.21Common StockSEC:0001780664-26-000041:6
300 shares@ US$25.45Common StockSEC:0001780664-26-000041:7
9,181 shares@ US$25.350.0057% mcap2.1% of flowCommon StockSEC:0001780664-26-000039:3
11,881 shares@ US$12.140.0035% mcap1.3% of flowCommon StockSEC:0001780664-26-000039:0
11,881 shares@ US$26.410.0076% mcap2.8% of flowCommon StockSEC:0001780664-26-000039:1
11,881 shares@ US$12.140.0035% mcap1.3% of flowCommon StockSEC:0001780664-26-000039:2
2,700 shares@ US$26.070.0017% mcap0.6% of flowCommon StockSEC:0001780664-26-000039:4
11,881 shares@ US$12.140.0035% mcap1.3% of flowCommon StockSEC:0001780664-26-000039:5
11,881 shares@ US$25.500.0074% mcap2.7% of flowCommon StockSEC:0001780664-26-000039:6
11,881 shares@ US$12.140.0034% mcap1.5% of flowCommon StockSEC:0001780664-26-000037:0
9,381 shares@ US$27.360.0060% mcap2.6% of flowCommon StockSEC:0001780664-26-000037:1
1,100 shares@ US$28.210.0007% mcap0.3% of flowCommon StockSEC:0001780664-26-000037:2
901 shares@ US$29.710.0006% mcap0.3% of flowCommon StockSEC:0001780664-26-000037:3
499 shares@ US$30.530.0004% mcap0.2% of flowCommon StockSEC:0001780664-26-000037:4
11,881 shares@ US$12.140.0033% mcap1.4% of flowCommon StockSEC:0001780664-26-000037:5
11,881 shares@ US$26.400.0073% mcap3.2% of flowCommon StockSEC:0001780664-26-000037:6
11,881 shares@ US$12.140.0034% mcap1.5% of flowCommon StockSEC:0001780664-26-000037:7
11,881 shares@ US$25.660.0071% mcap3.1% of flowCommon StockSEC:0001780664-26-000037:8
6,444 shares@ US$30.000.0045% mcap16.4% of flowCommon StockSEC:0001820885-26-000025:0
25 of 360 declarations
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp. is a U.S.-listed biotechnology company trading on the Nasdaq market in the United States, with headquarters in Seattle, Washington. The company was founded in 2009 as Adaptive TCR Corporation and later renamed Adaptive Biotechnologies Corporation in 2011. Its strategy has been built around a differentiated scientific thesis: using the biology of the adaptive immune system, and specifically the information contained in T-cell and B-cell receptors, to create clinical diagnostics and, longer term, therapeutic applications. For international investors, Adaptive is best viewed as a platform-style healthcare company that monetizes a proprietary immune-sequencing engine across multiple end markets.
The business is organized around two complementary segments. The commercial diagnostics business is anchored by clonoSEQ, a minimal residual disease (MRD) test used primarily in hematologic oncology, including multiple myeloma, certain leukemias, and lymphomas. Built on next-generation sequencing, clonoSEQ is the company’s lead revenue driver and a central asset in the growing precision-medicine ecosystem. The second pillar is Immune Medicine, which includes research and discovery capabilities such as immunoSEQ and data-driven collaborations aimed at identifying novel immune targets and applications. Together, these segments give Adaptive exposure to both clinical diagnostics and the monetization of high-value immune data.
Read moreShow less
From a competitive perspective, Adaptive occupies a specialized niche rather than competing as a broad-based diagnostics player. Its potential advantage lies in the depth of its immune repertoire data, the proprietary nature of its platform, and the link it can establish between sequencing, biological interpretation, and clinical utility. That makes the company strategically interesting, but it also means it operates in a demanding environment where reimbursement, regulatory evidence, and clinical adoption are critical to sustained growth.
Recent developments have been constructive. In 2025 reporting, management highlighted accelerating MRD revenue growth, stronger clonoSEQ volumes, and profitability in the MRD business. The company also noted expanded Medicare coverage for clonoSEQ in mantle cell lymphoma recurrence monitoring, which is an important support factor for adoption. In addition, recent SEC Form 4 insider transaction filings indicate ongoing insider activity, consistent with a public company in active capital-markets follow-up. Overall, Adaptive Biotechnologies remains a high-quality, technology-driven biotech story with an established commercial product base, but one that still depends on continued clinical uptake and disciplined execution on the Nasdaq in the United States.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
